Aytu BioScience

Aytu Biopharma, Inc. is a specialty pharmaceutical company, which focuses on identifying, acquiring, and commercializing novel products. Its products include Adzenys ER, Adzenys XR-ODT, Cotempla XR-ODT, Karbinal ER, Poly-Vi-Flor, Tri-Vi-Flor, Generic Tussionex, Tuzistra XR and ZolpiMist. The company was founded on August 9, 2002 and is headquartered in Englewood, CO.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Aytu BioScience reports robust Q3 performance, eyes growth through innovation

Aytu BioScience delivered strong financial results in Q3 2024, with notable revenue and margin improvements. The company's strategic focus on specialty pharmaceuticals and operational efficiency bodes well for future growth. While challenges like supply chain disruptions exist, Aytu is poised for continued success through innovation and market opportunities.

Aytu BioScience reports robust earnings, focuses on growth strategies

Aytu BioScience demonstrated strong financial performance with improved EBITDA and strategic repositioning
While facing challenges in certain portfolio revenues, the company is focused on growth opportunities
Strategic initiatives like the RxConnect program and product expansion are key strengths
Addressing market challenges and seizing growth opportunities will be crucial for future success

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Aytu Biopharma, Inc. is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. It operates through the Rx and Consumer Health segments. The RX segment consists of various prescription pharmaceutical products sold through third parties. The Consumer Health segment includes various consumer health products sold directly to consumers. Its products include Adzenys ER, Adzenys XR-ODT, Cotempla XR-ODT, Karbinal ER, Poly-Vi-Flor, Tri-Vi-Flor, Generic Tussionex, Tuzistra XR, and ZolpiMist. The company was founded on August 9, 2002 and is headquartered in Englewood, CO.

ENGLEWOOD, CO / ACCESSWIRE / January 5, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, today announced a 1-for-20 reverse stock split of its outstanding common stock, effective at 12:01 a.m. Eastern time on January 6, 2023.

Aytu BioPharma Announces 1-for-20 Reverse Stock Split

After losing some value lately, a hammer chart pattern has been formed for Aytu BioPharma Inc. (AYTU), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Bears are Losing Control Over Aytu BioPharma Inc. (AYTU), Here's Why It's a 'Buy' Now

Adzenys XR-ODT Total Prescription (TRx) Unit Growth Driven by a Combination of Continued Sales Force Execution, Leveraging of the Aytu RxConnect Patient Support Program, and a Positive Response to the Adderall® XR Supply Disruption Adzenys XR-ODT is the Only FDA-Approved, Extended-Release, Orally Disintegrating Tablet Formulation of Amphetamine Adzenys XR-ODT Continues to be Available as an FDA-Approved Bioequivalent Alternative to Adderall XR ENGLEWOOD, CO / ACCESSWIRE / November 30, 2022 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, today announced the highest weekly prescription total for Adzenys XR-ODT® (amphetamine) extended-release orally disintegrating tablets, CII, since the inception of the Aytu RxConnect patient support program. For the week ending November 18, 2022, a record 5,186 total prescriptions were filled for Adzenys XR-ODT.

Aytu BioPharma Announces Highest Weekly Adzenys XR-ODT(R) Prescriptions Generated Since Inception of RxConnect

ENGLEWOOD, CO / ACCESSWIRE / November 22, 2022 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, announced today that the Company received written notification from the Listing Qualifications Department of The Nasdaq Stock Market, LLC ("Nasdaq"), granting the Company's request for a 180-day extension to regain compliance with Nasdaq's minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the "Bid Price Rule"). The Company has until May 22, 2023 to meet the requirement.

Aytu BioPharma Receives a 180-Day Extension by Nasdaq to Regain Compliance with Bid Price Rule

Ranked 94th Fastest Growing Company in North America Ranked 21st Fastest Growing Life Sciences Company ENGLEWOOD, CO / ACCESSWIRE / November 17, 2022 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, announced today it has ranked 94th on the Deloitte Technology Fast 500™. Aytu ranked 21st among life sciences companies and is ranked for the second year in a row.

Aytu BioPharma Ranked Among Fastest-Growing Companies in North America on Deloitte's Technology Fast 500(TM) for Second Year in a Row

ENGLEWOOD, CO / ACCESSWIRE / November 16, 2022 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, announced the passing of Michael Macaluso, Co-Founder and founding board member of Aytu. "On behalf of Aytu BioPharma, our employees, our Board of Directors, and the Denver-area life sciences community, we extend our deepest condolences to Mike's family and friends," said Josh Disbrow, Chief Executive Officer of Aytu BioPharma.

Aytu BioPharma Announces the Passing of Co-Founder and Board Member Michael Macaluso

Aytu BioPharma, Inc. (NASDAQ:AYTU ) Q1 2023 Earnings Conference Call November 14, 2022 4:30 PM ET Company Participants Roger Weiss - Lytham Partners Josh Disbrow - CEO Mark Oki - CFO Conference Call Participants Jennifer Kim - Cantor Fitzgerald Operator Good afternoon, ladies and gentlemen, and welcome to the Aytu BioPharma Fiscal 2023 Q1 Results Call. At this time, all participants are placed on a listen-only mode and the floor for questions and comments after the presentation.

Aytu BioPharma, Inc. (AYTU) Q1 2023 Earnings Call Transcript

Record Quarterly Net Revenue of $27.7 Million Driven by 34% Growth in Rx Segment Positive Adjusted EBITDA for the Quarter of $1.4 Million Leadership Changes Implemented to Focus on Commercial Operations Company to Host Conference Call Today at 4:30pm ET ENGLEWOOD, CO / ACCESSWIRE / November 14, 2022 / Aytu BioPharma, Inc. (the Company or "Aytu") (Nasdaq:AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, today announced financial and operational results for the first quarter of fiscal year 2023 for the period ended September 30, 2022. Q1 2023 Commercial Highlights (3 months ending September 30, 2022) Total net revenue was $27.7 million, a new quarterly record, and an increase of 26% over the $21.9 million in net revenue in the year ago quarter.

Aytu BioPharma Reports Record Quarterly Revenue and Positive Adjusted EBITDA in First Quarter of Fiscal Year 2023

Amendment of Secured Loan Agreement Extends Interest-Only Period to January 2024 Amendment Defers Over $3 Million in Principal Payments Beyond 2023 Note Matures in January 2025, with Additional Extensions of the Interest-Only Period Available, Subject to Achievement of Certain Milestones ENGLEWOOD, CO / ACCESSWIRE / October 25, 2022 / Aytu BioPharma, Inc. (the Company or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced an agreement with the Avenue Venture Opportunities Fund, L.P. ("Avenue Venture Debt Fund" or "Avenue") to extend the interest-only period of the Company's existing senior secured loan facility held with Avenue.

Aytu BioPharma Announces Agreement with Avenue Venture Debt Fund to Extend Interest-Only Period of Company's Term Loan

Following a corporate review, Aytu BioPharma is indefinitely suspending clinical development and removing expenses related to AR101/enzastaurin, Healight, and NT0502, and focusing on revenue growth and near-term cash flow generation Aytu is expecting to generate positive quarterly Adjusted EBITDA in the first half of calendar 2023 Expected future clinical development savings of more than $20M ENGLEWOOD, CO / ACCESSWIRE / October 13, 2022 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced a shift of the Company's strategy aimed at accelerating the growth of its commercial business and achieving profitability. As a result, the Company is announcing the indefinite suspension of its clinical development programs, including AR101/enzastaurin for the treatment of Vascular Ehlers-Danlos Syndrome (VEDS).

Aytu BioPharma Announces Strategic Shift to Focus on Commercial Operations and Indefinite Suspension of Clinical Development Programs

Adzenys XR-ODT is FDA-Approved as Bioequivalent to Adderall XR Reported Supply Disruptions of Adderall XR Generic Equivalents Have the Potential to Affect Patient Access to ADHD Medications ENGLEWOOD, CO / ACCESSWIRE / October 5, 2022 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, with a development pipeline addressing rare, pediatric-onset disorders, today announced the continuing availability of Adzenys XR-ODT® (amphetamine) extended-release orally disintegrating tablets, CII in response to numerous reported supply disruptions affecting generic Adderall® XR (mixed salts amphetamine) extended-release capsule, CII for the treatment of attention deficit hyperactivity disorder (ADHD). Adzenys XR-ODT is bioequivalent to Adderall XR and is the only FDA-approved, extended-release, orally-disintegrating tablet formulation of amphetamine.

Aytu BioPharma Announces Continuing Availability of ADHD Medication Adzenys XR-ODT(R) in Response to Reported Generic Adderall(R) XR Supply Disruptions

Start Time: 16:30 January 1, 0000 5:12 PM ET Aytu BioPharma, Inc. (NASDAQ:AYTU ) Q4 2022 Earnings Conference Call September 27, 2022, 16:30 PM ET Company Participants Josh Disbrow - Chairman and CEO Mark Oki - CFO Robert Blum - Lytham Partners Conference Call Participants Vernon Bernardino - H.C. Wainwright Sumant Kulkarni - Canaccord Operator Good afternoon everyone and welcome to Aytu BioPharma's Fourth Quarter and Fiscal Year 2022 Financial Results Conference Call.

Aytu BioPharma, Inc. (AYTU) CEO Josh Disbrow on Q4 2022 Results - Earnings Call Transcript

ENGLEWOOD, CO / ACCESSWIRE / September 20, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, with a development pipeline addressing rare, pediatric-onset disorders, will report financial results for its fourth quarter and fiscal year ended June 30, 2022, after the market close on Tuesday, September 27, 2022. The Company has scheduled a conference call that same day, Tuesday, September 27, 2022, at 4:30 pm ET, to review the results.

Aytu BioPharma to Report Fourth Quarter and Fiscal 2022 Financial Results on September 27, 2022

This Fourth Patent for AR101/Enzastaurin Strengthens and Broadens the Intellectual Property Portfolio Surrounding the Treatment of Inherited Vascular Disorders Including Vascular Ehlers-Danlos Syndrome (VEDS). Multiple Patent Families Filed in Key Global Markets ENGLEWOOD, CO / ACCESSWIRE / September 14, 2022 / Aytu BioPharma, Inc. (the Company or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, with a development pipeline addressing rare, pediatric-onset disorders, today announced the addition of a fourth patent to the intellectual property suite surrounding AR101/Enzastaurin.

Aytu BioPharma Announces Addition of Fourth Patent License for AR101/Enzastaurin

ENGLEWOOD, CO / ACCESSWIRE / August 24, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, with a development pipeline addressing rare, pediatric-onset disorders, today announced that Aytu's management team will virtually present at, and participate in, the upcoming H.C. Wainwright 24th Annual Global Investment Conference and Lytham Partners Fall 2022 Investor Conference.

Aytu BioPharma to Participate in September 2022 Investor Conferences

First Issued U.S. Patent Covers Methods of Treating a Broad Range of Inherited Aortic Aneurism and Related Conditions Including Vascular Ehlers-Danlos Syndrome Multiple Patent Families Filed in Key Global Markets ENGLEWOOD, CO / ACCESSWIRE / August 16, 2022 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced that the U.S. Patent and Trademark Office has issued a new patent, No. 11,273,148 (the "'148 patent"), for AR101/Enzastaurin.

Aytu BioPharma Announces Issuance of Its First Patent for AR101/Enzastaurin

ENGLEWOOD, CO / ACCESSWIRE / August 15, 2022 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced the closing of its previously announced underwritten public offering of (i) 21,505,814 shares of its common stock, and, in lieu of common stock to certain investors that so chose, pre-funded warrants to purchase 1,750,000 shares of its common stock, and (ii) accompanying warrants (the "Common Warrants") to purchase 23,255,814 shares of its common stock (the "Offering"), resulting in gross proceeds of $10.0 million, assuming none of the accompanying Common Warrants issued in the Offering are exercised. The shares of common stock (or pre-funded warrants) and the accompanying Common Warrants were issued separately but purchased together in this Offering.

Aytu BioPharma Announces Closing of $10.0 Million Registered Public Offering

ENGLEWOOD, CO / ACCESSWIRE / August 9, 2022 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced the pricing of its underwritten public offering of (i) 21,505,814 shares of its common stock, and, in lieu of common stock to certain investors that so chose, pre-funded warrants to purchase 1,750,000 shares of its common stock, and (ii) accompanying warrants (the "Common Warrants") to purchase 23,255,814 shares of its common stock (the "Offering"). The shares of common stock (or pre-funded warrants) and the accompanying Common Warrants will be issued separately but can only be purchased together in this Offering.

Aytu BioPharma Announces Pricing of Public Offering

ENGLEWOOD, CO / ACCESSWIRE / August 8, 2022 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced the launch of an underwritten public offering of shares of its common stock or, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock, and accompanying warrants to purchase its common stock (the "Offering"). All of the securities in the Offering will be sold by Aytu.

Aytu BioPharma Announces Launch of Public Offering

ENGLEWOOD, CO / ACCESSWIRE / July 26, 2022 / Aytu BioPharma, Inc. (the "Company") (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced that Chief Executive Officer Josh Disbrow and Chief Financial Officer Mark Oki will participate in the Canaccord Genuity 42nd Annual Growth Conference being held August 8-11, 2022 at the InterContinental Hotel in Boston, MA. The Company will conduct one-on-one meetings throughout Tuesday, August 9th and Wednesday, August 10th and will present a corporate overview at 4:00 p.m.

Aytu BioPharma to Participate in the Canaccord Genuity 42nd Annual Growth Conference

ENGLEWOOD, CO / ACCESSWIRE / June 29, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced the appointment of Vivian Liu to the company's board of directors, effective July 1, 2022. Ms. Liu will serve as an independent director and as a member of the Nominating & Corporate Governance Committee.

Aytu BioPharma Announces the Appointment of Vivian Liu to the Company's Board of Directors

ENGLEWOOD, CO / ACCESSWIRE / June 13, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced that the company will be participating in the Lytham Partners Summer 2022 Investor Conference taking place virtually on June 21-22, 2022. The Company's webcast presentation will be available for viewing at 9:00 am ET on Tuesday, June 21, 2022, on the Company's website (https://irdirect.net/AYTU/corporate_document/2009) or at https://wsw.com/webcast/lytham5/aytu/2067180.

Aytu BioPharma to Participate in the Lytham Partners Summer 2022 Investor Conference

Quarterly Net Revenue Increased 79% Year-Over-Year to $24.2 Million, the Highest Revenue in Company History Strategic Priorities Focused on Driving Revenue Growth, Increasing Financial Efficiencies and Performance and Preparing Pipeline for Long-term Value Creation ENGLEWOOD, CO / ACCESSWIRE / May 16, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today reported financial results for its fiscal 2022 third quarter, ended March 31, 2022 and outlined its key strategic priorities. "In our fiscal third quarter and throughout 2022, we continued to make solid progress in growing our commercial businesses and developing our product candidate pipeline, and the operational improvements we've implemented following the Neos acquisition are being realized," said Josh Disbrow, chief executive officer of Aytu BioPharma.

Aytu BioPharma Reports Third Quarter 2022 Financial Results and Outlines Key Strategic Priorities

Preclinical Proof-of-Concept Study Demonstrates Effectiveness of Healight in Delaying Time to Development of Ventilator-Associated Pneumonia ENGLEWOOD, CO / ACCESSWIRE / April 25, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced positive results from a preclinical pilot study showing that administration of its Healight™ ultraviolet light A (UVA) endotracheal catheter delayed the time to development of ventilator-associated pneumonia (VAP) in a novel porcine model. Healight is the company's patented, investigational medical device technology employing proprietary methods of administering intermittent UVA light delivered via a novel respiratory endotracheal catheter.

Aytu BioPharma Announces Positive Preclinical Data in Ventilator-Associated Pneumonia with its Novel, Proprietary Healight(TM) Delivery Technology

Checkmate Pharmaceuticals

Toughbuilt Industries Inc

Here's what you need to know about trading penny stocks on April 19th The post Hot Penny Stocks to Buy? 3 to Watch As CMPI Stock Shoots Up 320% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

News for Aytu BioScience Stock (AYTU)